Biohaven Ltd. (BHVN34)

Overview

Biohaven Ltd. is a biopharmaceutical company engaged in discovering, developing, and commercializing treatments across three major areas: immunology, neuroscience, and oncology. With a global presence, Biohaven is committed to advancing a diverse pipeline of promising therapeutic candidates meant to address complex diseases with significant unmet medical needs. The company's comprehensive approach spans a wide range of conditions, from neurological and neuropsychiatric disorders to autoimmune diseases and cancer. Biohaven, initially known as Biohaven Research Ltd., underwent a rebranding to Biohaven Ltd. in September 2022, marking a new phase in its corporate evolution. Additionally, it has a history as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd. and was established in New Haven, Connecticut, in 2022. Biohaven's strategic collaborations with leading academic institutions and industry partners, including Yale University, AstraZeneca, and Katholieke Universiteit Leuven, underscore its commitment to innovation and the translation of scientific research into clinically meaningful therapeutics.

Products and Services

Biohaven Ltd. is focused on developing a broad portfolio of innovative treatments in various stages of clinical development:

• Troriluzole - Currently in Phase 3 clinical trials, Troriluzole is designed for treating neurological and neuropsychiatric illnesses by modulating glutamate levels, offering hope for conditions such as Alzheimer's disease and anxiety disorders.
• BHV-5500 - Targets post-synaptic NMDA receptors to inhibit glutamate signaling. This product is being explored for its potential role in neurological disorders where glutamate plays a key role.
• Taldefgrobep Alfa - In Phase 3 clinical trials, Taldefgrobep Alfa shows promise in treating spinal muscular atrophy and obesity, addressing major gaps in current therapeutic options.
• BHV-7000 - This candidate is in Phase 2/3 clinical trials, aiming to treat a range of conditions, including focal and generalized epilepsy, bipolar disorder, and major depressive disorder, through mechanisms that remain under exploration.
• BHV-2100 - Still in the early Phase 1 clinical trials, BHV-2100 is exploring new frontiers in the treatment of migraines and neuropathic pain, conditions affecting millions globally.
• BHV-8000 - Targets early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities, and is in Phase 1 clinical trials. This indicates Biohaven's commitment to tackling neurodegenerative diseases.
• BHV-1300 to BHV-1600 - This range includes candidates in Phase 1 clinical trials for autoimmune and cardiovascular conditions, such as rheumatoid arthritis and dilated cardiomyopathy, showcasing Biohaven's dedication to a diverse set of diseases.
• BHV-1100 & BHV-1500 - Focusing on oncology, these candidates are in early-stage trials for multiple myeloma and Hodgkin's lymphoma, respectively, as well as preclinical stages for targeting carcinomas, bringing new hope to cancer patients.

Through these efforts, Biohaven Ltd. embodies a forward-thinking approach to pharmaceutical development, leveraging cutting-edge science and strategic partnerships to foster innovation and provide new solutions for patients worldwide.